Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 401

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 2
Chunk 401
---
 quarter of 2025. These increases were partially offset by reduced expenses following the discontinuation of our Tdap program in late 2024.

As we continue to progress our clinical and preclinical stage pipeline, we expect research and development expenses to continue to represent a substantial portion of our expenses and to continue to increase, both in dollar amount and proportion of total expense, in future years.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of compensation and related costs for our commercial support personnel, medical education professionals, and personnel in executive and other administrative functions, including legal, finance and information technology; costs for outside services such as sales and marketing, post-marketing studies of HEPLISAV-B, accounting, commercial development, consulting, business development, investor relations and insurance; legal costs that include corporate and patent-related expenses; allocated facility costs and non-cash stock-based compensation.

33

The following is a summary of our selling, general and administrative expenses (in thousands, except for percentages): 

Selling, General and Administrative:Three Months EndedSeptember 30,Increase (Decrease) from 2024 to 2025Nine Months EndedSeptember 30,Increase (Decrease) from 2024 to 202520252024$%20252024$%Compensation and related personnel costs$17,018 $16,933 $85 1%$52,118 $53,610 $(1,492)(3%)Outside services12,019 15,551 (3,532)(23%)50,818 41,652 9,166 22%Facility costs2,429 1,874 555 30%7,795 6,648 1,147 17%Non-cash stock-based compensation8,620 8,703 (83)(1%)27,392 26,878 514 2%Total selling, general and administrative$40,086 $43,061 $(2,975)(7%)$138,123 $128,788 $9,335 7%     

Selling, general and administrative expenses decreased by $3.0 million for the three months ended September 30, 2025, compared to the same period in 2024, primarily due to marketing campaign expenses incurred in the three months ended September 30, 2024, that did not recur in the same period in 2025. Selling, general and administrative expenses